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ABSTRACT
Introduction: A relatively novel application for
dermoscopy and reflectance confocal
microscopy (RCM) is their use in the
monitoring of topical treatment response for
non-melanoma skin cancer. Actinic keratosis
(AK) is the early phase of a multistep biologic
continuum leading to invasive squamous cell
carcinoma. A number of topical therapies are
now available for the treatment of AK but their
disadvantages include long treatment duration
and prolonged local reactions. Ingenol
mebutate is a newer therapy for AK which is
only applied for 2 or 3 days.
Case Report: Dermoscopy and RCM findings in
two patients with AK treated with ingenol
mebutate confirm that it induces rapid lesion
necrosis and specific neutrophil-mediated,
antibody-dependent cellular cytotoxicity.
Necrosis occurs via mitochondrial membrane
disruption, with subsequent eradication of
residual tumor cells via transient inflammation.
Local skin reactions to ingenol mebutate should
be considered part of the drug’s mechanism of
action rather than an adverse effect.
Conclusion: Ingenol mebutate is a valuable
therapy for the treatment of AK. This case
report adds further evidence to the usefulness
of dermoscopy and RCM in the assessment and
monitoring of treatment outcome.
Keywords: Actinic keratosis; Dermoscopy;
Field cancerization; Ingenol mebutate;
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INTRODUCTION
Treatments for the so-called field cancerization
in actinic keratosis (AK) include imiquimod,
fluorouracil, diclofenac and photodynamic
therapy [1, 2]. Drawbacks to the self-applied
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topical therapies currently available include
long treatment duration and consequently
prolonged local reactions, which could lead to
less-than-ideal adherence to therapy. Recently,
ingenol mebutate gel has been developed as a
new topical agent for the treatment of AK and
approved by the US Food and Drug
Administration and European Medicines
Agency. It is a macrocyclic diterpene ester,
extracted from the plant Euphorbia peplus,
which has been previously used as a
traditional remedy for common skin lesions,
including skin cancer [3, 4]. Its mechanism of
action is to induce rapid and direct cell death
and an immune response mediated by specific
activation of protein kinase C delta, including
neutrophil-mediated oxidative burst and
clearance of tumors [5–7]. Thus, local skin
reactions (LSR) can range from mild
inflammation to severe vesiculation, pustules
and erosions [8]. Dermoscopy and reflectance
confocal microscopy (RCM) are currently the
most used noninvasive imaging techniques that
help clinicians not only to achieve high
diagnostic accuracy for skin cancer therapies,
but also to monitor treatment over time [9, 10].
Maier et al. recently reported successful
noninvasive monitoring of morphological
changes in AKs treated with ingenol mebutate
using a combination of optical coherence
tomography and RCM [11]. This type of
monitoring was superior to clinical evaluation
to detect nonresponding lesions.
Herein, we report two patients treated with
ingenol mebutate gel and monitored over time
by means of dermoscopy and RCM to assess skin
changes and treatment response.
Case 1
A 74-year-old man with skin phototype II had
several AKs on his left cheek (Fig. 1). No
previous treatments for AKs were performed.
Dermoscopically, the AKs were typified by a
reddish pseudo network and whitish scales.
Topical treatment with ingenol mebutate was
initiated and, after 7 days, a moderate-to-severe
reaction was noticed with confluent
vesicopustules observed clinically and
dermoscopically. After 15 days, complete
healing of the treated area was noted, as well
as a complete treatment response with no
residual AKs. At baseline, RCM revealed typical
findings seen in AKs, such as the presence of
parakeratosis and irregular keratinocytes
(Fig. 2). Notably after 7 days, vesicle formation
with several inflammatory cells was seen
followed, after 30 days, by a complete recovery
of the epidermis that showed regularly spaced
keratinocytes with a well-defined contour.
Case 2
A 67-year-old man with skin phototype II had
several AKs on his forehead (Fig. 3).
Dermoscopically all AKs were typified by a red
pseudo network and focal whitish scales. RCM
depicted the presence of parakeratosis, scales
and severely atypical keratinocytes. Topical
treatment with ingenol mebutate was initiated
and, after 7 days, erythema and vesicles located
within the treated area were present.
Interestingly, RCM revealed the presence of
vesicles and, at higher magnification, large
cells with lobed nuclei corresponding to
neutrophils were detected together with
necrotic keratinocytes (Fig. 4). Cytology smear
of the pustules and vesicles has been performed
(Papanicolaou test) to correlate the RCM
findings: necrotic keratinocytes (in pink) are
seen together with inflammatory cells and
neutrophils with lobed nuclei (Fig. 5).
After 15 days, a complete response was noted
with healing of the treated area that appeared
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significantly better than the surrounding
non-treated area (Fig. 6). Both dermoscopy and
RCM confirmed the clinical response by
showing normal skin and regular
keratinocytes, respectively.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
Fig. 1 a A 74-year-old man with several AKs on his left
cheek. b, e After 7 days’ treatment with ingenol mebutate, a
moderate-to-severe reaction is visible clinically and
dermoscopically, with the occurrence of confluent vesicles
and pustules. c, f After 15 days, complete healing of the
treated area is seen, with absence of residual AKs.
d Dermoscopically, AKs are typified by a reddish pseudo
network and whitish scales. AK Actinic keratosis
Fig. 2 a At baseline, RCM (0.5 9 0.5 mm) reveals the
typical findings seen in AKs, such as the presence of
parakeratosis and irregular keratinocytes. b After 7 days,
vesicles formation with several inflammatory cells are seen,
followed, after 30 days, by a complete recovery of the
epidermis that shows regularly spaced keratinocytes with a
well-defined contour (c). RCM Reflectance confocal
microscopy, AK Actinic keratosis
Dermatol Ther (Heidelb) (2016) 6:81–87 83
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
DISCUSSION
AK is the early phase of a multistep biologic
continuum leading to invasive squamous cell
carcinoma [1, 12]. Currently little is known
about factors predicting which lesions have the
potential to become invasive squamous cell
carcinoma and which are likely to remain
confined to the epidermal layer. Based on the
concept that AK is a very early malignant lesion,
there is consensus that patients with AK should
be treated and periodically followed-up [2].
During the past two decades, new and
effective treatment options have been
developed and are currently available on the
market. Different therapeutic approaches are
employed depending on whether the patient
has single, isolated lesions or so-called field
cancerization where multiple AKs are present
along with coexisting subclinical lesions [2].
Ingenol mebutate has recently been
approved for use as a topical treatment for AK
in the US and Europe. The drug is a
field-directed therapy and it is
self-administered over two consecutive days
for lesions of the trunk and extremities and
over three consecutive days for lesions of the
face and scalp. The rate of complete clearance
was higher with ingenol mebutate than with
placebo (42.2% vs. 3.7%, P\0.001) in four
randomized controlled trials [13]. LSR include
erythema, flaking or scaling, crusting, swelling,
vesiculation, pustulation, and erosion or
ulceration [8]. Analysis of four randomized
controlled trials has shown that ingenol
mebutate has promising characteristics given
its shorter treatment course, and overall
Fig. 3 a A 67-year-old man with several AKs on his
forehead. b, d, e Dermoscopically all AKs are typified by a
red pseudo network and focal whitish scales. c RCM
(0.5 9 0.5 mm) depicts the presence of parakeratosis
(arrows), scales (asterisk) and f severely atypical
keratinocytes (arrows). AK Actinic keratosis,
RCM Reflectance confocal microscopy
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Fig. 4 a After 7 days treatment. b Erythema and vesicles
located within the treated area are present. c RCM
(0.5 9 0.5 mm) reveals the presence of vesicles and, at
higher magnification, d large cells with lobed nuclei
corresponding to neutrophils (arrow) are seen together
with necrotic keratinocytes (arrow) (e). RCM Reflectance
confocal microscopy
Fig. 5 Smear test (papanicolaou test) after 7 days treatment. a Overview image (magnification 209) displaying necrotic
keratinocytes (arrows). b High magnification (409) image showing neutrophils (arrows)
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intensity and duration of LSR measured with a
global LSR score [13].
In our two cases we demonstrated the in vivo
skin changes occurring during ingenol
mebutate treatment by using dermoscopy and
RCM. Both cases were typified by the
occurrence of vesicles and pustules formed by
serum and inflammatory cells, respectively.
Notably, using RCM we were able to visualize
the presence of neutrophils within the observed
lesions. It is well known that neutrophils are
among the first appearing inflammatory cells
migrating towards the site of inflammation.
They migrate through the blood vessels, then
through interstitial tissue in a process called
chemotaxis. They are the predominant cells in
pus, accounting for its whitish/yellowish
appearance seen clinically and
dermoscopically. Another relevant RCM
finding in our case is that there is a necrosis
occurring at epidermal level that is composed of
necrotic polygonal and detached keratinocytes
as result of the direct and fast destruction of
cells.
CONCLUSION
Taken together, our dermoscopy and RCM
findings confirm that ingenol mebutate has a
dual mechanism of action: (1) rapid lesion
necrosis and (2) specific neutrophil-mediated,
antibody-dependent cellular cytotoxicity.
Because of the rapid destruction of AKs after
application of ingenol mebutate gel, treatment
is necessary for only 2 or 3 days. The necrosis of
cytologically atypical cells occurs by disrupting
the mitochondrial membrane and thus, with
subsequent eradication of residual tumor cells
via transient inflammation on the site of
application. Dermoscopy and confocal
microscopy have shown their capability to
assess microscopically and non-invasively the
possibility to monitor treatment reaction and
shed new light into the in vivo mechanism of
action of this new drug.
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